Text Size

Effects of Probiotics Supplementation on Intestinal Microbiome in Malignancy Pts(Get Pelvic/Abdominal Rtx) (RTxIMprobio)

This study is currently recruiting participants.
Verified April 2013 by Seoul National University Hospital
Sponsor:
Information provided by (Responsible Party):
Seoul National University Hospital
ClinicalTrials.gov Identifier:
NCT01706393
First received: August 31, 2012
Last updated: April 18, 2013
Last verified: April 2013
History of Changes

August 31, 2012
April 18, 2013
October 2012
July 2013   (final data collection date for primary outcome measure)
Changes of gut microbial communities in malignancy patients receiving pelvic/abdominal radiotherapy after probiotics administration to prevent radiation enteropathy. [ Time Frame: 42 days ] [ Designated as safety issue: No ]
  • Comparison of overall microbial communities in fecal samples between probiotics treated patients and control cancer patients receiving radiation therapy.
  • To determine preventing effect of probiotics against radiation enteropathy, all the bacterial species level taxon derived from fecal samples of cancer patients will be identified by massive sequencing analysis and relative abundance of each taxon between two groups will be statistically compared.
  • In addition, overall microbial composition, kind of species and their abundance, in two groups will be compared with clustering method such as UPGMA and PCoA and the variation values between two groups will be calculated.
  • In the current study, we will determine the effectiveness of probiotics for the prevention of radiation induced complications with these two comparative analysis methods.
Same as current
Complete list of historical versions of study NCT01706393 on ClinicalTrials.gov Archive Site
Prevention of any grade of diarrhea and gastrointestinal symptoms [ Time Frame: 42 days ] [ Designated as safety issue: No ]
  • Gastrointestinal symptoms will be scored according the Gastrointestinal symptom rating scale before and after RTx.
  • Diarrhea will be graded weekly according the Common Toxicity Criteria system.
Same as current
Not Provided
Not Provided
 
Effects of Probiotics Supplementation on Intestinal Microbiome in Malignancy Pts(Get Pelvic/Abdominal Rtx)
Double Blind Placebo Controled Randomized Trial, Effects of Probiotics Supplementation on Intestinal Microbiome in Malignancy Patients Who Get Pelvic/Abdominal Radiotherapy

The purpose of this study is to evaluate the effect of probiotics to improve the intestinal microbiome in malignancy patients who get pelvic/abdominal radiotherapy.

Pelvic/abdominal radiotherapy carries a risk of complications. Acute complications include diarrhea, abdominal pain, inflammatory change in the small intestine. Radiation creates changes in bacterial microbiome, the vascular permeability of the mucosal cells and in intestinal motility. Probiotics were known to improve gastrointestinal function. This is a randomized, double-blind, placebo-controlled study involving 26 patients designed to evaluate the effect of probiotics to change the intestinal microbiome in in patients undergoing concurrent pelvic/abdominal RT.
Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Basic Science
Cancer
  • Dietary Supplement: probiotics (six probiotic cultures)
    Effects of probiotics supplementation on intestinal microbiome; 2capsule bid orally for six weeks, 1capsule(500mg) Started eating probiotics one week prior of radiation therapy.
  • Dietary Supplement: Placebo
    Placebo intake for 6 weeks(including 5weeks of Rtx) and it take one tablet twice a day.
  • Experimental: probiotics

    Probiotics supplementation group. Probiotics intake for 6 weeks(including 5weeks of Rtx) and it take one tablet twice a day.

    Probiotics is composed of Lactobacillus acidophilus, Streptococcus thermophilus, Bifidobacterium lactis, L. rhamnosus, B. longum and B. bifidum.

    Intervention: Dietary Supplement: probiotics (six probiotic cultures)
  • Placebo Comparator: placebo

    Placebo group. Placebo intake for 6 weeks(including 5weeks of Rtx) and it take one tablet twice a day.

    Placebo is composed of starch.Probiotics and placebo were similar in appearance, taste.

    Intervention: Dietary Supplement: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
26
July 2013
July 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients who current diagnosis of gynecologic cancer or rectal cancer and never previously received radiation therapy and will use for the first time radiotherapy at department of radiation oncology, Seoul National University Hospital.
  • ECOG performance status (PS) of 0, 1, or 2.
  • signed written informed consent.
  • Patients who get pelvic/abdominal radiotherapy.

Exclusion Criteria:

  • People who use antibiotics that can affect intestinal microorganism growth within one month before the study.
  • Patients who use probiotics within one month before the study.
  • Patients received neoadjuvant chemotherapy.
  • Acute enteritis symptoms (diarrhea, abdominal pain, nausea, vomiting) for the patient.
  • Patients diagnosed with inflammatory bowel disease.
  • Patients suspected gastrointestinal infections and other infectious diseases.
  • Suspected infections from blood tests : Excessive rise in WBC, ESR, CRP
  • Suspected renal insufficiency from blood tests
Both
18 Years to 75 Years
No
Contact: Hak Jae Kim, MD +82-2-2072-2520 khjae@snu.ac.kr
Contact: Seung Wan Kang, MD,PhD +82-2-747-7422 drdemian@snu.ac.kr
Korea, Republic of
 
NCT01706393
SNUH-Cell-01
Yes
Seoul National University Hospital
Seoul National University Hospital
Not Provided
Principal Investigator: Hak Jae Kim, MD Seoul National University Hospital
Seoul National University Hospital
April 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP